Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, is fully committed to supporting the national effort against COVID-19 with all available resources. Since the start of the crisis, Quirónsalud has worked in close and trustful cooperation with national and regional healthcare authorities to provide the best possible treatment to the greatest possible number of patients.

Quirónsalud’s network currently comprises about 400 ICU beds for adults in almost 50 hospitals across Spain. The company is undertaking significant efforts to further increase this number in the short term, while continuing to treat other patients who urgently need medical support such as for chemotherapy, giving birth, and other emergencies.

Despite the high number of suspected and confirmed COVID-19 cases entering Quirónsalud’s hospitals, the company has kept every hospital fully operational. This is to a large extent due to the outstanding commitment of Quirónsalud’s medical and nursing staff, who deserve the utmost recognition and gratitude. So far, Quirónsalud has also been able to secure sufficient quantities of medical materials for all its hospitals, despite rapidly rising demand for critical supplies.

In the course of the formal declaration of a ‘State of Alarm’, the Spanish government has temporarily obtained the right to direct all hospitals in the country, allowing the healthcare authorities to leverage all available resources to treat COVID-19 patients as effectively as possible. Such an option is embedded in the established crisis management plans of many other European countries as well. Quirónsalud fully supports this measure, as it allows centralized capacity management, and hence rapid responses to changing circumstances and a full dedication of the entire system to fight the coronavirus.

Rumors about a “nationalization” of Spain’s private hospital system are clearly wrong and without any basis. Quirónsalud continues to manage its hospitals, and is already operating the additional beds requested by the authorities, in the joint effort against the COVID-19 threat for the benefit of Spain and the broader society.

Our Annual Report 2019 is now available as a full-content PDF download and as an online short-version with the highlights. Annual Report (PDF)  Online short-version

Our Annual Report 2019 is now available as a full-content PDF download and as an online short-version with the highlights. Annual Report (PDF)  Online short-version

Curalie, a subsidiary of Fresenius, has acquired Digitale Gesundheitsgruppe (DGG), one of its main competitors in Germany. Curalie and DGG both develop digital healthcare offerings to help patients with chronic illnesses. DGG targets family and specialist physicians with its “TeLiPro” telemedicine platform, while Curalie develops digital solutions for rehabilitation and aftercare. Combining the two companies creates the first provider that in all sectors of healthcare can digitally support patients during outpatient and inpatient care and through to aftercare.

Curalie, a subsidiary of Fresenius, has acquired Digitale Gesundheitsgruppe (DGG), one of its main competitors in Germany. Curalie and DGG both develop digital healthcare offerings to help patients with chronic illnesses. DGG targets family and specialist physicians with its “TeLiPro” telemedicine platform, while Curalie develops digital solutions for rehabilitation and aftercare. Combining the two companies creates the first provider that in all sectors of healthcare can digitally support patients during outpatient and inpatient care and through to aftercare.

Sodium Chloride 3% is the newest addition to the company’s IV solution portfolio.

Fresenius Medical Care, the world’s leading provider of dialysis products and services, today announced that the U.S. Food and Drug Administration (FDA) has cleared Novalung®, a heart and lung support system for the treatment of acute respiratory or cardiopulmonary failure. Novalung is the first extracorporeal membrane oxygenation (ECMO) system to be cleared for more than six hours of use as extracorporeal life support. The company expects Novalung to be available within the U.S. mid-year 2020.

Patients in acute respiratory or cardiopulmonary failure often struggle to get oxygen into their bloodstream or expel carbon dioxide out of their bodies, resulting in dangerously low levels of oxygen. This acute low oxygen state can result from a wide range of conditions.

The Novalung ECMO system pumps and oxygenates a patient’s blood, reducing the stress on damaged heart and lungs. Novalung offers a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings such as intensive care units, operating rooms, cardiac catheterization labs, and emergency departments.  

The use of Novalung as an ECMO device for critical care has several benefits, including minimizing the need for invasive ventilation, the ability to provide support after multi-organ injuries, and better survival outcomes for patients in cardiac arrest.

Contact

T: +49 (0) 6172 608-4030
leif.heussen@fresenius.com

Documents

Text as PDF document (PDF, 69 KB)

The market research institute Potentialpark has honored the global healthcare group Fresenius for the ninth consecutive year as the German company with the best overall Internet offering for job applicants.

In Potentialpark’s 2020 study, Fresenius not only took first place in the overall category for all career-relevant online activities but won in three of the four individual categories: Online Application Management, Mobile, and Career Website. The company was second in the Social Media category.

Potentialpark has carried out an annual study of German companies’ online offerings for job applicants since 2002. For this year’s study, Potentialpark assessed the online activities of 140 German companies according to more than 300 criteria. More than 46,000 students and graduates around the world were surveyed about their preferences.

“We are delighted to once again receive confirmation of the high quality of our Internet offering for job applicants,” said Michael Lehmann, Senior Vice President Corporate Human Resources of Fresenius. “In the past year we have expanded it with a digital onboarding portal, and are already at work on our next enhancements: We are internationalizing some of our social media channels for potential applicants. And we’re developing a construction kit for the web, so that country units of the Fresenius Group can put together their own career portals, set up to meet their specific requirements.”